Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice

Clinical Immunology

Volumn 123, Issue 1, 2007, Pages 95-104

  Link, Jason M ^a   Rich, Cathleen M ^a   Korat, Maya ^a   Burrows, Gregory G ^b,c   Offner, Halina ^a,b   Vandenbark, Arthur A ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Autoimmunity; Experimental autoimmune encephalomyelitis; HLA DR2; Minimum effective dose; Multiple sclerosis; Myelin oligodendrocyte glycoprotein; Recombinant TCR ligand

Indexed keywords

HLA DR2 ANTIGEN; LIGAND; MONOMER; MYELIN BASIC PROTEIN; RECOMBINANT RECEPTOR; RECOMBINANT T LYMPHOCYTE RECEPTOR LIGAND; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RELAPSE; SINGLE DRUG DOSE; TRANSGENIC MOUSE;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GLYCOPROTEINS; HLA-DR2 ANTIGEN; HUMANS; LIGANDS; MALE; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; RECURRENCE;

EID: 33947152923     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.12.002     Document Type: Article

References (28)

1. Burrows G.G., Bebo Jr. B.F., Adlard K.L., Vandenbark A.A., and Offner H. Two-domain MHC class II molecules form stable complexes with myelin basic protein 69-89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis. J. Immunol. 161 (1998) 5987-5996
2. Burrows G.G., Adlard K.L., Bebo Jr. B.F., Chang J.W., Tenditnyy K., Vandenbark A.A., and Offner H. Regulation of encephalitogenic T cells with recombinant TCR ligands. J. Immunol. 164 (2000) 6366-6371
3. Vandenbark A.A., Rich C., Mooney J., Zamora A., Wang C., Huan J., Fugger L., Offner H., Jones R., and Burrows G.G. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. J. Immunol. 171 (2003) 127-133
4. Huan J., Subramanian S., Jones R., Rich C., Link J., Mooney J., Bourdette D.N., Vandenbark A.A., Burrows G.G., and Offner H. Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch. J. Immunol. 172 (2004) 4556-4566
5. Rich C., Link J.M., Zamora A., Jacobsen H., Meza-Romero R., Offner H., Jones R., Burrows G.G., Fugger L., and Vandenbark A.A. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur. J. Immunol. 34 (2004) 1251-1261
6. Woods A., Chen H.Y., Trumbauer M.E., Sirotina A., Cummings R., and Zaller D.M. Human major histocompatibility complex class II-restricted T cell responses in transgenic mice. J. Exp. Med. 180 (1994) 173-181
7. Madsen L.S., Andersson E.C., Jansson L., Krogsgaard M., Andersen C.B., Engberg J., Strominger J.L., Svejgaard A., Hjorth J.P., Holmdahl R., Wucherpfennig K.W., and Fugger L. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. 23 (1999) 343-347
8. Madsen L., Labrecque N., Engberg J., Dierich A., Svejgaard A., Benoist C., Mathis D., and Fugger L. Mice lacking all conventional MHC class II genes. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 10338-10343
9. Burrows G.G., Chang J.W., Bachinger H.P., Bourdette D.N., Offner H., and Vandenbark A.A. Design, engineering and production of functional single-chain T cell receptor ligands. Protein Eng. 12 (1999) 771-778
10. Huan J., Meza-Romero R., Mooney J., Chou Y., Edwards D., Rich C., Link J., Vandenbark A.A., Bourdette D.N., Bachinger H.P., and Burrows G.G. Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity. J. Chem. Technol. Biotechnol. 80 (2005) 2-12
11. Ghabanbasani M.Z., Gu X.X., Spaepen M., Vandevyver C., Raus J., Marynen P., Carton H., and Cassiman J.J. Importance of HLA-DRB1 and DQA1 genes and of the amino acid polymorphisms in the functional domain of DR beta 1 chain in multiple sclerosis. J. Neuroimmunol. 59 (1995) 77-82
12. Chou Y.K., Culbertson N., Rich C., LaTocha D., Buenafe A.C., Huan J., Link J., Wands J.M., Born W.K., Offner H., Bourdette D.N., Burrows G.G., and Vandenbark A.A. T-cell hybridoma specific for myelin oligodendrocyte glycoprotein-35-55 peptide produced from HLA-DRB1*1501-transgenic mice. J. Neurosci. Res. 77 (2004) 670-680
13. Gaur A., Wiers B., Liu A., Rothbard J., and Fathman C.G. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 258 (1992) 1491-1494
14. Alvord Jr. E.C., Shaw C.M., Hruby S., and Kies M.W. Encephalitogen-induced inhibition of experimental allergic encephalomyelitis: prevention, suppression and therapy. Ann. N. Y. Acad. Sci. 122 (1965) 333-345
15. Levine S., Sowinski R., and Kies M.W. Treatment of experimental allergic encephalomyelitis with encephalitogenic basic proteins. Proc. Soc. Exp. Biol. Med. 139 (1972) 506-510
16. Kennedy M.K., Tan L.J., Dal Canto M.C., Tuohy V.K., Lu Z.J., Trotter J.L., and Miller S.D. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J. Immunol. 144 (1990) 909-915
17. Devaux B., Enderlin F., Wallner B., and Smilek D.E. Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide. J. Neuroimmunol. 75 (1997) 169-173
18. Smilek D.E., Wraith D.C., Hodgkinson S., Dwivedy S., Steinman L., and McDevitt H.O. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 9633-9637
19. Critchfield J.M., Racke M.K., Zuniga-Pflucker J.C., Cannella B., Raine C.S., Goverman J., and Lenardo M.J. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263 (1994) 1139-1143
20. Stern J.N., Illes Z., Reddy J., Keskin D.B., Sheu E., Fridkis-Hareli M., Nishimura H., Brosnan C.F., Santambrogio L., Kuchroo V.K., and Strominger J.L. Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11743-11748
21. Brod S.A., Lindsey J.W., and Wolinsky J.S. Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. Ann. Neurol. 47 (2000) 127-131
22. Ishioka G.Y., Adorini L., Guery J.C., Gaeta F.C., LaFond R., Alexander J., Powell M.F., Sette A., and Grey H.M. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides. J. Immunol. 152 (1994) 4310-4319
23. Bedford P., Garner K., and Knight S.C. MHC class II molecules transferred between allogeneic dendritic cells stimulate primary mixed leukocyte reactions. Int. Immunol. 11 (1999) 1739-1744
24. Herrera O.B., Golshayan D., Tibbott R., Ochoa F.S., James M.J., Marelli-Berg F.M., and Lechler R.I. A novel pathway of alloantigen presentation by dendritic cells. J. Immunol. 173 (2004) 4828-4837
25. Shoemaker M., Riddle K., Crane M.M., Clark R., and Walker M.R. Acquisition of functional MHC class II/peptide complexes by T cells during thymic development and CNS-directed pathogenesis. J. Perinatol. 22 (2002) 641-645
26. Itano A.A., and Jenkins M.K. Antigen presentation to naive CD4 T cells in the lymph node. Nat. Immunol. 4 (2003) 733-739
27. Marusic S., and Tonegawa S. Tolerance induction and autoimmune encephalomyelitis amelioration after administration of myelin basic protein-derived peptide. J. Exp. Med. 186 (1997) 507-515
28. Hendricks S.E., Olson C.H., and Pietropaolo M. Intratracheal administration to the lung enhances therapeutic benefit of an MBP peptide in the treatment of murine experimental autoimmune encephalomyelitis. Pharmacol., Biochem. Behav. 66 (2000) 337-342